Skip to main content

Main navigation

  • Expertise
  • Publications & Insights
  • People
  • Careers

Secondary navigation

  • Value added services
  • CSR
  • About us

SearchSearch results for: “”

258 results

Jeannette Vaude-Perrin

Of Counsel Luxembourg

Stibbe Luxembourg expands its service with the arrival of Of Counsel, Jeannette Vaude-Perrin

Stibbe reinforces its asset management/investment funds practice with the hire of Jeannette Vaude-Perrin as Of Counsel in its Luxembourg office.

Stibbe Luxembourg étend son offre de services avec la venue d'Of Counsel, Jeannette Vaude-Perrin

Stibbe renforce sa pratique de gestion d’actifs/fonds d’investissement avec la venue de Jeannette Vaude-Perrin en tant que Of Counsel.

Launch of Metaverse blog series

Stibbe launches a new blog series focusing on the legal challenges of the Metaverse. In our upcoming blog posts, we will discuss the legal challenges of NFTs, crypto-assets, Metaverse platforms, crypto exchanges, DAO, and many more.

Product counseling en intellectueel eigendom

In deze podcastaflevering van Stibbe Legal Insights spreken Femke van der Voort, gespecialiseerd in intellectueel eigendom, en Paul van der Hulst, mede-eigenaar en managing director van MoviĜo, over het beschermen van intellectuele eigendomsrechten.

Registratie UBO's in het UBO-register: terugmelding, handhaving en sanctionering

Vennootschappen en andere juridische entiteiten hadden tot 27 maart 2022 voor de registratie van hun UBO’s (ultimate beneficial owners) bij het Nederlandse UBO-register. Het voldoen aan de UBO-registratie blijft actueel.

Stibbe advises Aedifica

Stibbe has advised Aedifica on the acquisition and lease of a care residence to be constructed in Lelystad and the acquisition and lease of a recently completed care residence in Zwolle. 

Breaking news from the CJEU: no SPCs for new therapeutic applications

On 9 July 2020, the Grand Chamber of the CJEU ruled on the interpretation of Article 3(d) of Regulation 469/2009 concerning the supplementary protection certificate (CCP) for medicinal products.

Stibbe advises leading pharmaceutical company

Stibbe assisted a leading pharmaceutical company in identifying the most cost-effective way to obtain in Belgium an improved pricing and reimbursement for new fixed-dose combination products composed of off-patent ingredients.

Stibbe advises Canon

Advising Canon in connection with their dispute with the State of the Netherlands on the procurement of framework contracts. Case won up to and including the Supreme Court.

Stibbe advises Mylan

Stibbe advises global pharmaceutical company Mylan on the merger control aspects of its USD 7.2 billion acquisition of Swedish drugmaker Meda.

Stibbe advises Aedifica

Stibbe advises Aedifica, a Belgian listed company investing in health care real estate, on reaching agreement to acquire two new senior housing sites in Lochem and Rotterdam.

Stibbe advises Aedifica

Stibbe advises Aedifica, a Belgian listed company investing in health care real estate, on the acquisition of a new senior housing site in Arnhem.

This is the second investment of Aedifica in The Netherlands. Aedifica has developed a portfolio of health

Stibbe advises Sonova Holding AG

Stibbe has advised Sonova Holding AG on its acquisition of AudioNova B.V. from HAL Investments. The value of AudioNova is EUR 830 million.

Stibbe advises Aedifica

Stibbe advises Aedifica, a Belgian listed company investing in health care real estate, on its acquisition of four senior housing sites in The Netherlands.

Stibbe represents Mylan

On 27 July 2015, Teva Pharmaceutical Industries announced that it has withdrawn its previously announced hostile bid to acquire Mylan N.V. Stibbe represented Mylan in this successful takeover defence and advised Mylan on both litigation and EU competition

Stibbe advises Tornier

Stibbe advises Tornier N.V. on its merger with Wright Medical Group, Inc. in an all stock transaction with a combined equity value of approximately $3.3 billion.

Stibbe advises Mylan

Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business.

Pagination

  • Previous page
  • Page 10
  • Current page 11
  • Page 12
  • Page 13
  • Next page
Reset filters
Date
Content type
  • Article (133)
  • Event (9)
  • Inside Stibbe (10)
  • Interview (1)
  • Matter (59)
  • Podcast (6)
  • People (40)
Expertise
  • (-) Financial Regulation (176)
  • (-) Healthcare and Life Sciences (85)
  • Audit Firms and Accountancy (76)
  • Banking and Finance (437)
  • Capital Markets (251)
  • Compliance, Sanctions and Risk (162)
  • Corporate and M&A (884)
  • Corporate Investigations (32)
  • Criminal Law and Enforcement (148)
  • Employment, Benefits and Pensions (419)
  • Energy, Industry and Climate (320)
  • Environment and Planning (913)
  • ESG & Sustainability (307)
  • EU and Competition Law (486)
  • Infrastructure and Mobility (205)
  • Insurance (36)
  • Intellectual Property (120)
  • Investment Funds (147)
  • Litigation and Arbitration (435)
  • Mass Litigation (92)
  • Privacy and Data Protection (206)
  • Private Equity (200)
  • Procurement Law (128)
  • Public Law (1219)
  • Real Estate (487)
  • Restructuring and Insolvency (116)
  • Sports (27)
  • Tax (454)
  • Tech (197)
  • Technology, Media and Telecommunications (339)
  • Unfair Competition and Consumer Protection (200)
Jurisdiction
  • BE Law (42)
  • EU Law (68)
  • LU Law (20)
  • NL Law (160)
Language
  • Dutch (48)
  • English (202)
  • French (8)

Footer main navigation

  • Expertise
  • Publications & Insights
  • People
  • Careers
© 2025 Stibbe

Footer navigation

  • Contact
  • Disclaimer
  • General Conditions
  • Register of legal practice areas
  • Privacy and Cookie Policy
  • Important Information